Skip to main content

Tweets

NEW biomarkers in #MAS 1️⃣ IL-18 (available at some 🏥)⭐️ 2️⃣ S100A12 3️⃣ CXCL9/10 🚨When suspecting #MAS, don’t ignore the possibility of a monogenic disorder! 🎙️ Dr. Sophie Georgin-Lavialle 🇫🇷 #macrophage #EULAR2024 #genetics #rheumx https://t.co/Uot3JjrWs8
Artem Minalyan, MD, DABOM @AMinalyan ( View Tweet )
1 year 10 months ago
DMOADs in #osteoarthritis at #EULAR2024: 1) Tonia Vincent: StepUp OA endotype SF proteomics —> endothelial to mesenchymal transition proteins. 2) Phil Conaghan: proregenerative (& degeneration slowing) therapies in pipeline. 3) @Larhumato: novel RCT designs & structure outcomes

Tuhina Neogi, MD, PhD @Tuhina_Neogi ( View Tweet )

1 year 10 months ago
POS0277: proof of concept: Prophlx with canakinumab x 1 dose rather than steroids/colch/NSAIDS when starting pegloticase with MTX in pts with active, refractory gout: 11 pts: #gout flares 0 (compared 54% in MIRROR-C), infusion rxn 0, no safety signal @rheumnow https://t.co/4qFnQTOuq0
TheDaoIndex @KDAO2011 ( View Tweet )
1 year 10 months ago
Recommendation for management of fatigue in people with rheumatic disease. Considering fatigue as a surrogate for inflammation and changing medication accordingly is part of it. I will also add yearly blood work including: 1- VitD 2-HBA1c and LDl 3-TsH. https://t.co/3QvPqMxZSN
Nouf Al hemmadi @NoufAhmedAlham2 ( View Tweet )
1 year 10 months ago
Enjoyed the #PolymyalgiaRheumatica session at #EULAR2024? Make sure to download our first atlas imaging article, where @drceowen, @drdavidliew et al. characterise PMR using whole-body PET/CT 👀 ➡️ https://t.co/tbu0DgAFIS https://t.co/W06YbYyjRx
Rheumatology & Rheumatology Advances in Practice @RheumJnl ( View Tweet )
1 year 10 months ago
Mapping the knee #osteoarthritis joint-nerve interactome — presented by @AM_Malf at #EULAR2024. Anatomical and molecular neuroplasticity occurs during OA onset + progression in the joint and DRG. Cool imaging of nerves and their activity with lightsheet microscopy in mice https://t.co/cre6LEVhle
Tuhina Neogi, MD, PhD @Tuhina_Neogi ( View Tweet )
1 year 10 months ago
Maintenance of remission in GPA/MPA. RTX for 48 months sounds good to me. #EULAR2024 https://t.co/5YGwOHhCuX
Nouf Al hemmadi @NoufAhmedAlham2 ( View Tweet )
1 year 10 months ago
Potential efficacy of JAK inhibitors in VEXAS syndrome #EULAR2024 NZ https://t.co/HziLUgo1gA
Annals of the Rheumatic Diseases @ARD_BMJ ( View Tweet )
1 year 10 months ago
500+ pts AxSPA No difference in drug discontinuation between IL-17i, TNFi, IL23i over time Adjusted for CRP, co-medication w/ MTX + classic covariates IL-17i and IL-23i had experienced a higher number bDMARD failures #EULAR2024 POS0259 @RheumNow https://t.co/F3B6uXyAca
Aurelie Najm @AurelieRheumo ( View Tweet )
1 year 10 months ago
Cohort from Netherlands 400+ PsA pts IR first bioDMARD 300+ switched TNFi->IL-17i, 99 cycled TNFi->TNFi 3year retention rates 12 mo 75% cyclers 80% swappers 24mo 60% cyclers 56% swappers No difference in treatment failure or DAS28 CRP #EULAR2024 @RheumNow POS0278 https://t.co/J8ONjVAFqG
Aurelie Najm @AurelieRheumo ( View Tweet )
1 year 10 months ago
What is the meaning of mechanical stress-induced sacroiliac BMO MRI after childbirth in healthy women? 5yrs follow up MRI study shows: -decrease in BMO -1/3 BMO @ 5-year follow-up -15% ASAS definition of sacroiliitis -No correlation w/ symptoms @RheumNow #EULAR24 OP0222

Aurelie Najm @AurelieRheumo ( View Tweet )

1 year 10 months ago
Understudied neurological involvement 🧠 in RA in pts > 65 vs. matched HC -larger lateral cerebral ventricles -brain atrophy -shrinkage of thalamus + frontal cortical regions -association w/ clinical depression @RheumNow POS0148 #EULAR2024 https://t.co/2mV4qGyBtW
Aurelie Najm @AurelieRheumo ( View Tweet )
1 year 10 months ago
×